About Tianjin Chase Sun Pharmaceutical Company

The company was founded in 1996 and listed on the first batch of GEM in the country in 2009 (stock code: 300026). It is a state-owned holding enterprise under the State Assets Administration Commission. The controlling shareholder, Chengdu Xingcheng Investment Group Co., Ltd., is one of the world's top 500 companies, ranking 466. The business covers 6 major sectors, including traditional Chinese medicine formula granules, finished drugs, raw materials, medical devices, medical health services, and a smart pharmaceutical device supply chain. It has 2 national R&D platforms: a national enterprise technology center and a national and local joint engineering research center for key technologies for traditional Chinese medicine formula granules. Mainly engaged in the production, operation and research and development of pharmaceuticals and medical devices. Xuebijing injections, moxifloxacin hydrochloride injections (Anrotai), low molecular weight heparin calcium injections (Bopuqing), traditional Chinese medicine formula granules, medical devices, pharmaceutical excipients, etc. Corporate honors: It has received many honors such as a national key high-tech enterprise, a national technological innovation demonstration enterprise, the National Advanced Collective for Poverty Alleviation, and the Tianjin Science and Technology Progress First Prize.